Literature DB >> 22405258

Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis.

Udayakumar Navaneethan1, Gursimran Kochhar, Preethi G K Venkatesh, Brian Lewis, Bret A Lashner, Feza H Remzi, Bo Shen, Ravi P Kiran.   

Abstract

BACKGROUND: Annual surveillance colonoscopy to detect colon cancer is recommended for patients with primary sclerosing cholangitis (PSC) and ulcerative colitis (UC). Limited data currently support these recommendations.
OBJECTIVE: To study whether a relationship exists between the severity and duration of PSC and the risk of colon cancer and dysplasia (colon neoplasia).
DESIGN: Retrospective, longitudinal study.
SETTING: Tertiary-care referral center. PATIENTS: Information pertaining to duration of PSC, UC, requirement for orthotopic liver transplantation, and time to diagnosis of colon neoplasia was obtained for patients with PSC and UC. Patients were evaluated and followed-up from 1985 to 2011 at a single institution. MAIN OUTCOME MEASUREMENTS: Association between the severity and duration of PSC-UC and the time of occurrence of colon neoplasia.
RESULTS: Of 167 patients with a combined diagnosis of PSC-UC, 55 had colonic neoplasia on colonoscopy. Colonic neoplasia occurred more frequently within 2 years of a combined diagnosis of PSC-UC (6.6/100 patient-years of follow-up) than after 8 years from PSC-UC (2.7/100 patient-years of follow-up). On proportional hazards analysis, older age at PSC diagnosis (hazard ratio 1.23 for every 5 years; 95% confidence interval, 1.03-1.34; P = .014) increased the risk of colon neoplasia. LIMITATIONS: Retrospective study.
CONCLUSION: In this study, the severity of PSC was not significantly associated with the risk of colon neoplasia. Patients with PSC and UC have a high risk of colon neoplasia soon after the coexistence of the two diseases is discovered. Older age at PSC diagnosis increases this risk.
Copyright © 2012 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22405258     DOI: 10.1016/j.gie.2012.01.015

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  9 in total

Review 1.  Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.

Authors:  María Rojas-Feria; Manuel Castro; Emilio Suárez; Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 2.  Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis.

Authors:  Jonathan D Hansen; Sonal Kumar; Wai-Kit Lo; David M Poulsen; Umme-Aiman Halai; Kathy C Tater
Journal:  Dig Dis Sci       Date:  2013-07-30       Impact factor: 3.199

3.  Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance.

Authors:  James H Tabibian; Ahmad H Ali; Keith D Lindor
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-07

Review 4.  Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease.

Authors:  Guru Trikudanathan; Preethi G K Venkatesh; Udayakumar Navaneethan
Journal:  Drugs       Date:  2012-12-24       Impact factor: 9.546

Review 5.  Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk.

Authors:  Udayakumar Navaneethan
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-06-20

6.  Primary sclerosing cholangitis and the risk of colon neoplasia in patients with Crohn's colitis.

Authors:  Udayakumar Navaneethan; Tarun Rai; Preethi Gk Venkatesh; Ravi P Kiran
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-02-26

7.  Comparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn's disease.

Authors:  Udayakumar Navaneethan; Preethi Gk Venkatesh; Ramprasad Jegadeesan; Vennisvasanth Lourdusamy; Jeffrey P Hammel; Ravi P Kiran; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-10-29

Review 8.  Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features.

Authors:  Carolina Palmela; Farhad Peerani; Daniel Castaneda; Joana Torres; Steven H Itzkowitz
Journal:  Gut Liver       Date:  2018-01-15       Impact factor: 4.519

Review 9.  Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders.

Authors:  Stefano Mazza; Sara Soro; Maria Chiara Verga; Biagio Elvo; Francesca Ferretti; Fabrizio Cereatti; Andrea Drago; Roberto Grassia
Journal:  World J Hepatol       Date:  2021-12-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.